Ultragenyx Pharmaceutical | RARE - Net Income


Ultragenyx Pharmaceutical reported $-129M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Immunic USD -24.37M 2.99M Sep/2024
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Kyowa Hakko Kirin JPY 34.44B 18.16B Dec/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024